Who's in favor of translational cell therapy for stroke: STEPS forward please?
A consortium of translational stem cell and stroke experts from multiple academic institutes and biotechnology companies, under the guidance of the government (FDA/NIH), is missing. Here, we build a case for the establishment of this consortium if cell therapy for stroke is to advance from the laboratory to the clinic.
Chopp
Michael
M
Department of Neurology, Henry Ford Hospital, Detroit, MI, USA.
Steinberg
Gary K
GK
Kondziolka
Douglas
D
Lu
Mei
M
Bliss
Tonya M
TM
Li
Yi
Y
Hess
David C
DC
Borlongan
Cesario V
CV
D000047:Academies and Institutes; D000818:Animals; D064987:Cell- and Tissue-Based Therapy; D002986:Clinical Trials as Topic / Q000592:standards; D004353:Drug Evaluation, Preclinical / Q000592:standards; D006801:Humans; D009316:National Institutes of Health (U.S.); D017149:Private Sector; D033581:Stem Cell Transplantation; D020521:Stroke / Q000628:therapy*; D057170:Translational Research, Biomedical / Q000458:organization & administration*; D014481:United States; D014486:United States Food and Drug Administration